{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:39:29Z","timestamp":1793813969312,"version":"4.6.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.annonc.2021.04.012","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T13:15:15Z","timestamp":1619615715000},"page":"1111-1126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Practical considerations in screening for genetic alterations in cholangiocarcinoma"],"prefix":"10.1016","volume":"32","author":[{"given":"T.S.","family":"Bekaii-Saab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MOG.0000000000000611","article-title":"Molecular classification of cholangiocarcinoma","volume":"36","author":"Louis","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.clinre.2020.03.024","article-title":"Epidemiology of cholangiocarcinoma; United States incidence and mortality trends","volume":"44","author":"Gad","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","article-title":"Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States","volume":"16","author":"Mukkamalla","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.annonc.2021.04.012_bib6","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.04.012_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ejca.2010.02.005","article-title":"Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis","volume":"46","author":"Zhou","year":"2010","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.annonc.2021.04.012_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.04.012_bib10","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","volume":"37","author":"Lamarca","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2021.04.012_bib11","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/cncr.32463","article-title":"Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes","volume":"125","author":"Lowery","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.path.2018.02.005","article-title":"Cholangiocarcinoma","volume":"11","author":"Krasinskas","year":"2018","journal-title":"Surg Pathol Clin"},{"issue":"10","key":"10.1016\/j.annonc.2021.04.012_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.annonc.2021.04.012_bib16","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"7291","key":"10.1016\/j.annonc.2021.04.012_bib18","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"Hudson","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.04.012_bib19","doi-asserted-by":"crossref","first-page":"bar026","DOI":"10.1093\/database\/bar026","article-title":"International Cancer Genome Consortium Data Portal\u2014a one-stop shop for cancer genomics data","volume":"2011","author":"Zhang","year":"2011","journal-title":"Database (Oxford)"},{"issue":"11","key":"10.1016\/j.annonc.2021.04.012_bib22","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jclinpath-2015-203394","article-title":"Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","volume":"69","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Pathol"},{"issue":"17","key":"10.1016\/j.annonc.2021.04.012_bib24","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/hbsn.2019.08.05","article-title":"Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice","volume":"8","author":"Xue","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.annonc.2021.04.012_bib27","unstructured":"Javle MM, Murugesan K, Shroff RT, et\u00a0al. Profiling of cholangiocarcinomas (CCA) to identify genomic alterations, tumor mutational burden (TMB) and genomic loss of heterozygosity (gLOH). Paper presented at the Annual Meeting of the American Society of Clinical Oncology. May 31, 2019 to June 4, 2019; Chicago, IL."},{"issue":"24","key":"10.1016\/j.annonc.2021.04.012_bib28","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.04.012_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/PO.18.00414","article-title":"Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and western patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.04.012_bib31","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2021.04.012_bib32","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2021.04.012_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2020.38.4_suppl.578","article-title":"Primary versus metastatic intrahepatic cholangiocarcinoma: a comparative comprehensive genomic profiling (CGP) study","volume":"38","author":"Ross","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"issue":"8","key":"10.1016\/j.annonc.2021.04.012_bib35","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib38","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A\u00a0framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.04.012_bib39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.04.012_bib40","series-title":"Prescribing information: PEMAZYRE\u2122 (pemigatinib) tablets, for oral use","year":"2020"},{"issue":"30","key":"10.1016\/j.annonc.2021.04.012_bib41","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.04.012_bib43","doi-asserted-by":"crossref","first-page":"e15607","DOI":"10.1200\/JCO.2019.37.15_suppl.e15607","article-title":"Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA) [abstract e15607]","volume":"37","author":"Droz Dit Busset","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.04.012_bib44","doi-asserted-by":"crossref","first-page":"v276","DOI":"10.1093\/annonc\/mdz247.048","article-title":"Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations\/amplifications [abstract 3879]","volume":"30","author":"Droz Dit Busset","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.04.012_bib46","doi-asserted-by":"crossref","first-page":"AB051","DOI":"10.21037\/hbsn.2019.AB051","article-title":"A\u00a0phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions [abstract AB051. P-19]","volume":"8","author":"Javle","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.04.012_bib47","doi-asserted-by":"crossref","first-page":"AB065","DOI":"10.21037\/hbsn.2019.AB065","article-title":"Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results [abstract AB065 P-36]","volume":"8","author":"Ng","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib48","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A\u00a0phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 9","key":"10.1016\/j.annonc.2021.04.012_bib49","first-page":"ix46","article-title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's [abstract 1490]","volume":"29","author":"Tran","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2021.04.012_bib50","article-title":"Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma [abstract O-020]","volume":"28","author":"Goyal","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.04.012_bib51","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion\u2013positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"30","key":"10.1016\/j.annonc.2021.04.012_bib52","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2021.04.012_bib53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib54","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2021.04.012_bib55","article-title":"Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation","volume":"39","author":"Zhu","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2021.04.012_bib56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2019.37.4_suppl.187","article-title":"Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial [abstract 187]","volume":"37","author":"Wainberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.04.012_bib57","series-title":"Prescribing information: KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use","year":"2020"},{"issue":"8","key":"10.1016\/j.annonc.2021.04.012_bib58","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib61","doi-asserted-by":"crossref","first-page":"a004002","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2021.04.012_bib63","doi-asserted-by":"crossref","first-page":"100487","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib64","doi-asserted-by":"crossref","first-page":"e000446","DOI":"10.1136\/esmoopen-2018-000446","article-title":"Precision oncology: separating the wheat from the chaff","volume":"3","author":"Remon","year":"2018","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14737159.2019.1564043","article-title":"Should next-generation sequencing tests be performed on all cancer patients?","volume":"19","author":"McKenzie","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.annonc.2021.04.012_bib66","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/EDBK_174176","article-title":"Precision oncology: who, how, what, when, and when not?","volume":"37","author":"Schwartzberg","year":"2017","journal-title":"Am Soc of Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib67","first-page":"305","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2021.04.012_bib69","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Hepatobiliary Cancers. March 5, 2021 edition.\u00a02021."},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib70","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5582\/bst.2016.01048","article-title":"The current management of cholangiocarcinoma: a comparison of current guidelines","volume":"10","author":"Cai","year":"2016","journal-title":"Biosci Trends"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","article-title":"EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples","volume":"66","author":"Ellison","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"issue":"7","key":"10.1016\/j.annonc.2021.04.012_bib76","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib77","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/cancers10030072","article-title":"Update on immunohistochemistry for the diagnosis of lung cancer","volume":"10","author":"Inamura","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib78","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/atm.2016.12.33","article-title":"MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy","volume":"5","author":"Pilotto","year":"2017","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.annonc.2021.04.012_bib79","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.5858\/arpa.2018-0396-CP","article-title":"Performance comparison of different analytic methods in proficiency testing for mutations in the BRAF, EGFR, and KRAS genes: a study of the College of American Pathologists Molecular Oncology Committee","volume":"143","author":"Moncur","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcp\/aqw206","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"146","author":"Bartley","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.annonc.2021.04.012_bib81","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/molecules25081864","article-title":"Use of fluorescence in situ hybridization (FISH) in diagnosis and tailored therapies in solid tumors","volume":"25","author":"Chrzanowska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.annonc.2021.04.012_bib82","doi-asserted-by":"crossref","first-page":"20277","DOI":"10.1038\/srep20277","article-title":"Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer","volume":"6","author":"Dupouy","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-018-4755-5","article-title":"Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification","volume":"170","author":"Agersborg","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.annonc.2021.04.012_bib84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11864-019-0675-9","article-title":"Diagnosis and treatment of ALK aberrations in metastatic NSCLC","volume":"20","author":"Friedlaender","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib85","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5858\/arpa.2019-0085-OA","article-title":"Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization","volume":"144","author":"Huang","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib86","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib87","first-page":"1175","article-title":"Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data","volume":"58","author":"Gaber","year":"2017","journal-title":"Rom J Morphol Embryol"},{"key":"10.1016\/j.annonc.2021.04.012_bib88","doi-asserted-by":"crossref","unstructured":"Hollebecque A, Silverman IM, Owens S, et\u00a0al. Comprehensive genomic profiling and clinical outcomes in patients with fibroblast growth factor receptor rearrangement-positive cholangiocarcinoma treated with pemigatinib in the FIGHT-202 trial. Paper presented at the European Society for Medical Oncology (ESMO) Congress. September 27, 2019 to October 1, 2019; Barcelona, Spain.","DOI":"10.1093\/annonc\/mdz247.047"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib89","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1038\/s41598-018-22473-9","article-title":"A\u00a0simple and robust real-time qPCR method for the detection of PIK3CA mutations","volume":"8","author":"Alvarez-Garcia","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib90","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jmoldx.2014.06.008","article-title":"Seven novel probe systems for real-time PCR provide absolute single-base discrimination, higher signaling, and generic components","volume":"16","author":"Murray","year":"2014","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.annonc.2021.04.012_bib91","doi-asserted-by":"crossref","first-page":"757490","DOI":"10.1155\/2013\/757490","article-title":"Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods","volume":"2013","author":"Tuononen","year":"2013","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib92","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jmoldx.2018.09.007","article-title":"A\u00a0novel multiplex droplet digital PCR assay to identify and quantify KRAS mutations in clinical specimens","volume":"21","author":"Alcaide","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"issue":"11","key":"10.1016\/j.annonc.2021.04.012_bib94","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/PPO.0000000000000322","article-title":"Added value of whole-exome and transcriptome sequencing for clinical molecular screenings of advanced cancer patients with solid tumors","volume":"24","author":"Koeppel","year":"2018","journal-title":"Cancer J"},{"issue":"29","key":"10.1016\/j.annonc.2021.04.012_bib99","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","article-title":"Clinical and translational research challenges in biliary tract cancers","volume":"27","author":"Lamarca","year":"2020","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib100","first-page":"2854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"26","key":"10.1016\/j.annonc.2021.04.012_bib101","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1200\/JCO.19.01479","article-title":"Ethical framework for including research biopsies in oncology clinical trials: American Society of Clinical Oncology Research Statement","volume":"37","author":"Levit","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib102","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib103","doi-asserted-by":"crossref","first-page":"e0193802","DOI":"10.1371\/journal.pone.0193802","article-title":"Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling","volume":"13","author":"Plagnol","year":"2018","journal-title":"PLoS One"},{"issue":"41","key":"10.1016\/j.annonc.2021.04.012_bib104","doi-asserted-by":"crossref","first-page":"66595","DOI":"10.18632\/oncotarget.10704","article-title":"Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma","volume":"7","author":"Rachiglio","year":"2016","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.annonc.2021.04.012_bib105","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","article-title":"Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma","volume":"23","author":"Schwaederl\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.annonc.2021.04.012_bib106","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non\u2013small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2021.04.012_bib107","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00432-020-03267-x","article-title":"Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review","volume":"146","author":"Esagian","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/tlcr.2020.01.01","article-title":"Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications","volume":"9","author":"Pasquale","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.annonc.2021.04.012_bib109","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2020.38.15_suppl.4579","article-title":"Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): a comparative comprehensive genomic profiling (CGP) study","volume":"38","author":"Ross","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.04.012_bib110","doi-asserted-by":"crossref","first-page":"e000600","DOI":"10.1136\/esmoopen-2019-000600","article-title":"Development of circulating tumour DNA analysis for gastrointestinal cancers","volume":"5","author":"Nakamura","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.annonc.2021.04.012_bib111","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib114","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-019-09374-9","article-title":"Diagnosis of fusion genes using targeted RNA sequencing","volume":"10","author":"Heyer","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nprot.2014.058","article-title":"Targeted sequencing for gene discovery and quantification using RNA CaptureSeq","volume":"9","author":"Mercer","year":"2014","journal-title":"Nat Protoc"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib116","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jmoldx.2017.05.006","article-title":"Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors","volume":"19","author":"Reeser","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib117","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/cancers11091309","article-title":"RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples","volume":"11","author":"Kirchner","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"12","key":"10.1016\/j.annonc.2021.04.012_bib120","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.04.012_bib121","author":"Archer"},{"issue":"6","key":"10.1016\/j.annonc.2021.04.012_bib122","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.04.012_bib123","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","article-title":"Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management","volume":"20","author":"Hung","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib124","doi-asserted-by":"crossref","first-page":"12510","DOI":"10.1038\/s41598-017-12679-8","article-title":"Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches","volume":"7","author":"Vendrell","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2021.04.012_bib125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cancergen.2020.02.007","article-title":"Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by Illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN","volume":"243","author":"Qu","year":"2020","journal-title":"Cancer Genet"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib126","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00535-020-01735-2","article-title":"Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)","volume":"56","author":"Maruki","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2019-0441","article-title":"Guardant360 circulating tumor DNA assay is concordant with FoundationOne next-generation sequencing in detecting actionable driver mutations in anti-EGFR naive metastatic colorectal cancer","volume":"25","author":"Gupta","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2021.04.012_bib135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-030-24100-1_2","article-title":"Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer","volume":"1168","author":"Morganti","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.annonc.2021.04.012_bib136","doi-asserted-by":"crossref","DOI":"10.1515\/fhep-2019-0013","article-title":"Health economics tools and precision medicine: opportunities and challenges","volume":"23","author":"Veenstra","year":"2020","journal-title":"Forum Health Econ Policy"},{"key":"10.1016\/j.annonc.2021.04.012_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00311","article-title":"Economic evaluations of next-generation precision oncology: a critical review","volume":"2","author":"Weymann","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib138","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/cge.13199","article-title":"Application of next-generation sequencing to improve cancer management: a review of the clinical effectiveness and cost-effectiveness","volume":"93","author":"Tan","year":"2018","journal-title":"Clin Genet"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib139","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jval.2018.06.017","article-title":"Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions","volume":"21","author":"Phillips","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.annonc.2021.04.012_bib140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jmoldx.2018.04.002","article-title":"Validity of targeted next-generation sequencing in routine care for identifying clinically relevant molecular profiles in non-small-cell lung cancer: results of a 2-year experience on 1343 samples","volume":"20","author":"Legras","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"issue":"9","key":"10.1016\/j.annonc.2021.04.012_bib141","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41431-018-0194-3","article-title":"Correction: cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study","volume":"26","author":"Marino","year":"2018","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib142","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41431-017-0081-3","article-title":"Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study","volume":"26","author":"Marino","year":"2018","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.annonc.2021.04.012_bib143","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jval.2020.02.001","article-title":"Use of real-world evidence in US payer coverage decision-making for next-generation sequencing-based tests: challenges, opportunities, and potential solutions","volume":"23","author":"Deverka","year":"2020","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.annonc.2021.04.012_bib144","first-page":"936","article-title":"Consideration for employer-based and geographic attributes included in value assessment methods of next-generation sequencing tests","volume":"25","author":"Hart","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.annonc.2021.04.012_bib145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.6004\/jnccn.2015.0043","article-title":"Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in","volume":"13","author":"Trosman","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"23","key":"10.1016\/j.annonc.2021.04.012_bib146","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/jama.2018.4863","article-title":"Evolving payer coverage policies on genomic sequencing tests: beginning of the end or end of the beginning?","volume":"319","author":"Phillips","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2021.04.012_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non\u2013small-cell lung cancer using a decision analytic model","volume":"3","author":"Pennell","year":"2019","journal-title":"JCO Precis Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421011698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421011698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:04:20Z","timestamp":1760335460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421011698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0923753421011698"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.04.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical considerations in screening for genetic alterations in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}